Celgene Corp (CELG) 94.70 $CELG
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
Final Glance: Biotechnology companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene rose 2.4%
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Celgene (CELG) rose 2.4% to 95.66 as an Deutsche Bank analyst said upcoming clinical trial data on a Crohn's disease drug could lift shares. The analyst also touted Gilead Sciences (GILD), which fell 1.1% but is still up 16% in Aug.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Stocks Rise As Biotechs Lead; Amazon To Buy Twitch
at Investor's Business Daily - Tue Aug 26, 3:58PM CDT
Stocks were moderately higher Monday with biotech stocks leading the way. The Nasdaq and the Dow Jones industrial average rose 0.4% and the S&P 500 gained 0.5%. After the close, Amazon (AMZN) announced it was paying $970 million to buy Twitch, a live...
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
Celgene (CELG) Approaches New Upside Target of $94.87
Comtex SmarTrend(R) - Tue Aug 26, 9:01AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $93.13 today and has reached the first level of resistance at $94.13. Investors may be interested in a cross of the next upside pivot targets of $94.87 and $96.61.
3 Reasons Celgene Corporation's Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 7:49AM CDT
If you've been a long-term shareholder in Celgene stock you have very little to complain about. The company's core drug, Revlimid, a treatment for blood-borne cancers, has grown into what's expected to be a $5 billion blockbuster this year, and...
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.
Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...
Celgene Set to Possibly Pullback After Yesterday's Rally of 1.94%
Comtex SmarTrend(R) - Mon Aug 25, 3:58PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $92.12 to a high of $93.86. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $93.35 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.94% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 3:57PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $92.12 to a high of $93.86. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $93.35 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Higher With Biotechs Leading The Way
at Investor's Business Daily - Mon Aug 25, 3:34PM CDT
The stock market was moderately higher Monday, with the S&P 500 topping 2000 intraday for the first time. Biotechs led the way on the strength of a major takeover. The Nasdaq and Dow industrials rose 0.4% each; the S&P 500 gained 0.5%. Nasdaq volume...
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
Final Glance: Biotechnology companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene rose 2.4%
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Celgene (CELG) rose 2.4% to 95.66 as an Deutsche Bank analyst said upcoming clinical trial data on a Crohn's disease drug could lift shares. The analyst also touted Gilead Sciences (GILD), which fell 1.1% but is still up 16% in Aug.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Stocks Rise As Biotechs Lead; Amazon To Buy Twitch
at Investor's Business Daily - Tue Aug 26, 3:58PM CDT
Stocks were moderately higher Monday with biotech stocks leading the way. The Nasdaq and the Dow Jones industrial average rose 0.4% and the S&P 500 gained 0.5%. After the close, Amazon (AMZN) announced it was paying $970 million to buy Twitch, a live...
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
Celgene (CELG) Approaches New Upside Target of $94.87
Comtex SmarTrend(R) - Tue Aug 26, 9:01AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $93.13 today and has reached the first level of resistance at $94.13. Investors may be interested in a cross of the next upside pivot targets of $94.87 and $96.61.
3 Reasons Celgene Corporation's Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 7:49AM CDT
If you've been a long-term shareholder in Celgene stock you have very little to complain about. The company's core drug, Revlimid, a treatment for blood-borne cancers, has grown into what's expected to be a $5 billion blockbuster this year, and...
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.
Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...
Celgene Set to Possibly Pullback After Yesterday's Rally of 1.94%
Comtex SmarTrend(R) - Mon Aug 25, 3:58PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $92.12 to a high of $93.86. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $93.35 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.94% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 3:57PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $92.12 to a high of $93.86. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $93.35 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Higher With Biotechs Leading The Way
at Investor's Business Daily - Mon Aug 25, 3:34PM CDT
The stock market was moderately higher Monday, with the S&P 500 topping 2000 intraday for the first time. Biotechs led the way on the strength of a major takeover. The Nasdaq and Dow industrials rose 0.4% each; the S&P 500 gained 0.5%. Nasdaq volume...
